The impact of bcl-2 proto-oncogene expression on the pathogenesis and progression of prostate cancer was examined in a transgenic mouse model. Probasin-bcl-2 transgenic mice were crossed with TRAMP (TRansgenic Adenocarcinoma Mouse Prostate) mice that express the SV40 early genes (T/t antigens) under probasin control. Prostate size, cell proliferation, apoptosis, and the incidence and latency of tumor formation were evaluated. The double transgenic, probasin-bcl-2 X TRAMP F 1 (BxT) mice exhibited an increase in the wet weight of the prostate. This was associated with an increase in proliferation, attributable to T/t antigens, and a decrease in apoptosis attributable to bcl-2. The latency to tumor formation was also decreased in the BxT mice compared to the TRAMP mice. The incidence of metastases was identical in both the TRAMP and BxT mice. Lastly, the incidence of hormone-independent prostate cancer was reduced in the BxT mice compared to the TRAMP mice.
Introduction
Newly diagnosed prostate cancer is estimated to aect approximately 178 300 American men in 1999 (Landis et al., 1999) . Currently the most eective non-surgical treatment for prostate cancer is androgen-ablation therapy. While initially eective, most patients will relapse with androgen-independent prostate cancer, that is resistant to further therapeutic interventions. The acquisition of androgen-independent growth is associated with the increased expression of bcl-2 (McDonnell et al., 1992; Colombel et al., 1993) . Direct evidence of a growth advantage imparted by bcl-2 following androgen-ablation has been provided by studies using xenografts of androgen-sensitive prostate cancer cell lines. In these studies, the LNCaP and Dunning G prostate carcinoma cell lines were engineered to overexpress bcl-2 and grown as xenografts in nude mice (Rao et al., 1995; Westin et al., 1997; Beham et al., 1998) . Following castration the bcl-2 expressing tumors exhibited a signi®cant growth advantage compared to the control tumors. Thus, it appears that bcl-2 can enable prostate cancer cells to remain viable despite castrate levels of androgen. It is possible that one consequence of androgen-ablation therapy itself may be the selection or upregulation of bcl-2 in prostate cancer cells. It has also been suggested that bcl-2 may contribute to the therapeutic refractoriness of these neoplasms (Sullivan et al., 1998; Keshgegian et al., 1998) .
Inactivating somatic mutations of the p53 tumor suppressor gene have also been implicated in the pathogenesis and progression of prostate cancer (Heidenberg et al., 1996; Pettaway, 1998; Johnson and Handy, 1998) . Several studies have demonstrated that p53 protein expression serves as an adverse prognostic indicator in prostate cancer (Heidenberg et al., 1996; Bauer et al., 1995; Berner et al., 1993; Thomas et al., 1993) . On the basis of these observations, it might be anticipated that the inactivation of p53 and the expression of bcl-2 may each confer a growth advantage to prostate cancer cells as well as resistance to therapeutic cell death induction.
Transgenic mice were used to determine the eects of increased bcl-2 expression on the pathogenesis and progression of prostate cancer in vivo. The most extensively utilized transgenic model for prostate cancer is the TRAMP mouse (Greenberg et al., 1995; Gingrich, et al., 1996 Gingrich, et al., , 1997 . Probasin directed expression of SV40 early genes in the prostate results in an age-related progression from hyperplasia to metastatic disease by 28 weeks of age (Greenberg et al., 1995; Gingrich et al., 1996 Gingrich et al., , 1997 . The TRAMP model has also been used to investigate the mechanisms of androgen-independent progression (Gingrich et al., 1997) .
The probasin promoter, as in the TRAMP transgenic mice, was recently used to target bcl-2 speci®cally to the prostate in transgenic mice (Bruckheimer et al., 2000) . In this study we used genetic complementation to examine cooperation between bcl-2 and T antigen during in vivo multistep tumorigenesis was assessed by generating bcl-2 x TRAMP (BxT) mice. The BxT mice displayed increased prostate size, which was associated with a reduction in steady-state rates of apoptosis in prostatic glandular epithelial cells. Carcinoma in situ and invasive cancer developed in the BxT mice with a signi®cantly shorter latency compared to TRAMP mice. The incidence and rate of tumor metastases was similar in the BxT and TRAMP mice. Although the deregulated expression of bcl-2 alone does not result in transformation of prostatic glandular epithelium, it is able to cooperate with SV40 early genes and accelerate the development of prostate cancer in vivo.
Results

Generation of BxT mice
In order to directly assess the contribution of bcl-2 to multistep prostate carcinogenesis in vivo, probasin-bcl-2 mice were crossed with TRAMP transgenic mice. Expression of transgenic human bcl-2 and SV40 large T antigen (LTA) was con®rmed using Western blotting ( Figure 1a ) and immunohistochemical techniques (Figure 1b, c) . The amount of LTA protein was lower in both the ventral and dorsolateral prostates from BxT mice, 3.2-fold and 1.6-fold respectively, when compared to the TRAMP mice (Figure 1a) . Expression of both transgenes was limited to the prostatic glandular epithelium (Figure 1b, c) . Detectable levels of transgene expression were not observed in any other organ (not shown) as previously reported (Bruckheimer et al., 2000) .
Evidence of complementation in BxT mice
In order to determine if the increased expression of bcl-2 aected prostate size, wet weights of the ventral and dorsolateral prostates from control, bcl-2, TRAMP, and BxT mice were obtained from 8-and 12-week-old animals. Prostates from control littermate, bcl-2, TRAMP, and BxT transgenic mice at 8 weeks of age were not signi®cantly dierent in size ( Table 1) . The dorsal and ventral prostates from TRAMP and BxT mice were signi®cantly larger than either control littermate or bcl-2 mice at 12 weeks of age (Table 1) . Additionally, the dorsal and ventral prostate from BxT mice were signi®cantly larger than the corresponding lobes from the TRAMP mice at 12 weeks of age (Table 1) .
Incorporation of bromodeoxyuridine (BrdU) was used to assess rates of prostatic glandular epithelial cell proliferation in 12-week-old male mice. Rates of proliferation in dorsal and ventral prostates of control littermate and probasin bcl-2 mice ranged from 0.2+0.07% to 0.32+0.04% and were not signi®cantly dierent. However, the ventral and dorsolateral prostates of TRAMP and BxT mice exhibited a signi®cant increase (P40.005) in BrdU incorporation compared to both control littermate and probasin-bcl-2 mice (Figure 2 ). The rate of BrdU incorporation observed in the dorsal (8.08+1.0%) and ventral (5.78+0.62%) prostates of TRAMP mice was greater than that observed in BxT mice, 5.66+0.42% and 4.39+0.28%, respectively, (Figure 2 ) but this did not achieve a level of statistical signi®cance (P40.1).
Steady-state levels of apoptosis in the dorsal and ventral prostate were determined using the TUNEL technique to identify cells with fragmented DNA (Figure 3 ). Basal rates of apoptosis observed in the ventral and dorsal prostates from control littermate and probasin-bcl-2 transgenic mice were not signi®-cantly dierent. The mean apoptotic indices in the ventral and dorsal prostates of TRAMP mice were 1.96+0.41% and 0.84+0.14%, respectively, signi®-cantly greater (P40.005) than corresponding values in either control littermate or probasin-bcl-2 mice. Importantly, the apoptotic index in the ventral prostate The expression of human bcl-2 was determined in the ventral prostate of control littermate (WT), bcl-2, TRAMP, and BxT mice at 12 weeks of age using a monoclonal antibody against human bcl-2 (3006). (c) The expression of LTA was determined in the ventral prostate of control littermate (WT), bcl-2, TRAMP, and BxT mice at 12 weeks of age using a monoclonal antibody against LTA (2406) of BxT mice was 0.42+0.08% which was not signi®cantly dierent than control littermates but signi®cantly less than that observed in TRAMP ventral prostate. The apoptotic index for the dorsal lobe of the prostate in BxT mice was 0.68+0.07%, which was signi®cantly greater than that of control littermate and probasin-bcl-2 mice. Although the mean apoptotic index of the dorsal lobe of the prostate from BxT mice was less than that for the corresponding lobe from TRAMP mice, this did not achieve a level of statistical signi®cance.
Multistep prostate carcinogenesis
The light microscopic histologic appearance of prostates from control littermate, probasin-bcl-2, TRAMP, and BxT mice was evaluated at intervals ranging from 8 ± 28 weeks of age. This analysis provided the basis for developing a scheme to enable consistent classi®cation of the histologic alterations observed in the transgenic mice ( Figure 4 ). The histologically normal prostatic glandular epithelium consisted of a layer of columnar epithelial cells and basal epithelial cells. Low grade prostatic intraepithelial neoplasia (PIN) typically occurred focally within a gland. Foci of low grade PIN were 2-3 cell layers thick with cells possessing elongated nuclei and an increased nuclear/cytoplasmic ratio. The cells of low grade PIN exhibited minimal pleomorphism and were typically euchromatic. High grade PIN usually involved the entire surface of an individual gland forming villous projections into intact glandular lumenae ( Figure 4 ). Epithelial cell nuclei from areas of high grade PIN were more heterochromatic than low grade PIN and exhibited minimal to moderate pleomorphism. An intact basal cell component was discernible in both low and high grade PIN.
Carcinoma in situ (CIS) was characterized by cells possessing coarse chromatin, high nuclear/cytoplasmic ratio, extensive pleomorphism, and extensive cribiform architecture ( Figure 4 ). Frequently, the glandular lumen was completely replaced by neoplastic epithelial cells. Mitotic activity was evident and the basal cell layer was disrupted in CIS. Invasive carcinomas were characteristically poorly dierentiated. They grew as solid sheets of tumor cells with no discernible glandular structures. Smaller invasive tumors were as poorly dierentiated as larger tumors and were associated with a spectrum of other malignant and premalignant alterations within the prostate glands. Most commonly, the tumors were so extensive that it was not possible to determine the prostatic lobe of origin. Tumors displayed high rates of mitotic activity and foci of necrosis could be identi®ed. The prostates from probasin-bcl-2 transgenic mice and control littermates exhibited no evident histologic alterations over the period of observation. The incidence of low and high grade PIN was similar in TRAMP and BxT mice. These processes involved both the dorsal and ventral prostates. Histological evidence of CIS or invasive cancer was observed in the TRAMP and BxT mice as early as 8 weeks of age ( Figure 5 ). The frequency of CIS or invasive cancer was signi®cantly greater in BxT mice compared to TRAMP mice (P40.003) at 12 and 20 weeks of age ( Figure 5 ). Ultimately, all TRAMP mice develop prostate cancer as previously described (Greenberg et al., 1995; Hsu et al., 1998) .
The incidence of metastases were similar in TRAMP and BxT mice. Metastases were present in approximately 40% of tumor bearing mice. Metastases to regional lymph nodes were most common, however metastases to kidney, liver, and lung were also observed ( Figure 6 ). Interestingly, tumor metastases involving the kidney, but not other metastatic sites, were characteristically moderately to well-dierentiated, exhibiting distinct glandular components (Figure 6 ). These well-dierentiated metastases to kidney were observed even though the primary prostate tumors were poorly dierentiated. Metastases to bone were not identi®ed in this study. Larger tumors were also observed to involve adjacent pelvic structures, including the urinary bladder ( Figure 6 ) and colorectum by direct extension.
The incidence of androgen-independent prostate cancer
Because bcl-2 expression has previously been associated with advanced-stage relapsed human prostate cancer (McDonnell et al., 1992; Colombel et al., 1993) and to confer resistance to androgen deprivation in prostate cancer cells (Rao et al., 1995; Westin et al., 1997; Beham et al., 1998) it was of interest to determine if bcl-2 contributed to the development of androgen- independent cancer in this in vivo model system. Control littermate (n=10), probasin-bcl-2 (n=10), TRAMP (n=11), and BxT (n=9) mice were castrated at 12 weeks of age and prostates were harvested 12 weeks following castration. No tumors were observed in the prostates from control littermate and probasinbcl-2 mice, as anticipated. Prostate cancers were observed in 36% of the TRAMP mice 12 weeks following castration compared to only 11% in the BxT mice. Immunoblot analysis showed similar levels of murine bcl-2, bcl-x L , and bax protein in tumors arising spontaneously or following castration in TRAMP mice (not shown). Additionally, we have previously shown and con®rmed in this study that levels of transgenic bcl-2 protein are undetectable 14 days following castration (Bruckheimer et al., 2000) .
Discussion
We have recently reported the use of the probasin gene promoter to target expression of a human bcl-2 transgene speci®cally to prostatic glandular epithelial cells (Bruckheimer et al., 2000) . Enforced bcl-2 expression in this transgenic animal model did not demonstrably alter steady-state levels of proliferation or apoptosis and, consequently, prostate hyperplasia or neoplasia was not observed. However, bcl-2 conferred signi®cant protection against the eects of androgen deprivation in the prostates of probasin-bcl-2 transgenic mice following castration. It remained a matter of interest to determine whether bcl-2 could contribute to multistep prostate carcinogenesis.
The TRAMP model was generated by using a probasin promoter element to target SV40 early genes to the prostate (Greenberg et al., 1995; Gingrich et al., 1996) . The large T antigen is known to bind and inactivate the p53 and Rb tumor suppressor gene products which have been implicated in the pathogenesis of prostate cancer (Bookstein et al., 1990; Rubin et al., 1991) . The small t antigen is known to abrogate protein phosphatase 2A activity (Mateer et al., 1998) . TRAMP mice develop prostate carcinomas at a consistent and predictable rate involving approximately 50% of mice by 20 ± 22 weeks of age and 100% of mice by 28 ± 30 weeks of age (Gingrich et al., 1996; Hsu et al., 1998) . TRAMP mice, therefore, represent an unique model system to assess candidate cooperating genetic events acting to accelerate the pathogenesis of prostate cancer in vivo. By crossing the probasin-bcl-2 transgenic mice with the TRAMP mice, BxT mice were generated which simultaneously expressed both SV40 early genes and bcl-2 speci®cally in prostatic glandular epithelial cells.
Phenotypically the TRAMP and BxT mouse prostates were indistinguishable from those of probasin-bcl-2 transgenic or control littermate mice at 8 weeks of age. This observation con®rms the previously reported ®ndings in TRAMP mice (Gingrich et al., 1996) . However, by 12 weeks of age the dorsal and ventral prostates of TRAMP and BxT mice were signi®cantly larger than prostates from either control littermate or probasin-bcl-2 transgenic mice. Importantly, prostates from BxT mice were also signi®cantly larger than those of the TRAMP mice at 12 weeks of age providing gross evidence of cooperation between SV40 early genes and bcl-2. The increase in prostate wet weight in BxT mice corresponded histologically to a signi®cantly greater incidence of prostate carcinoma compared to TRAMP mice up to 20 weeks of age. By 20 weeks of age 100% of the BxT mice exhibited histologic evidence of prostate carcinoma compared to only 50% of prostates in TRAMP. Again, these results are very similar to those previously reported for TRAMP Figure 6 Histology of metastatic prostate cancers. Prostate tumors were obtained from TRAMP and BxT mice and the histology assessed in H&E stained sections using light microscopy (1206) mice (Gingrich et al., 1996 (Gingrich et al., , 1999 . These ®ndings provide compelling evidence that the deregulated expression of bcl-2 can contribute to multistep prostate carcinogenesis in vivo.
The mechanistic basis of the complementation between SV40 early genes and bcl-2 in this context is at present unknown. It is of interest in this regard, however, that bcl-2 provided signi®cant protection against apoptosis associated with the expression of SV40 early genes. The steady state levels of apoptosis and proliferation in the prostatic glandular epithelium of TRAMP mice was signi®cantly greater than that of control littermates. Expression of bcl-2, alone, provided no demonstrable enhancement of proliferation or reduction in steady-state levels of apoptosis consistent with our previously published observations (Bruckheimer et al., 2000) . Importantly, however, steady-state levels of apoptosis were signi®cantly reduced, to a level comparable to that of control littermate mice, in the ventral prostates of BxT mice compared to TRAMP mice. Additionally, although rates of proliferation, as assessed by BrdU incorporation, were diminished in the ventral prostates of BxT mice compared to TRAMP mice this did not achieve a level of statistical signi®cance. These ®ndings suggest that the functional basis of cooperation in this in vivo model of multistep prostate carcinogenesis may be attributable to the ability of bcl-2 to protect against apoptosis associated with SV40 early gene expression. It is of interest in this context that the simultaneous deregulation of cell death and cell proliferation has been shown to signi®cantly accelerate multistep carcinogenesis in other cell types (McDonnell, 1993) .
The molecular basis of the synergism between bcl-2 and SV40 early genes is unknown. The transformation ability of LTA has been linked to its physical interactions with other proteins including the retinoblastoma gene product (DeCaprio et al., 1988) , the p53 tumor suppressor gene (Linzer et al., 1979; Lane and Crawford, 1979) , hsp70 (May et al., 1991), and TFIID (Damania and Alwine, 1996) . The possibility that the observed complementation between bcl-2 and LTA may be attributable to any, or all, of these, or yet to be identi®ed, LTA interacting proteins, is speculative.
Upregulation of bcl-2 protein is associated with the acquisition of androgen-independent growth in human prostate cancer (McDonnell et al., 1992; Colombel et al., 1993) . Enforced expression of bcl-2 has also been shown to provide protection against androgen deprivation and a signi®cant growth advantage in prostate cancer cells (Westin et al., 1997; Beham et al., 1998; Rao et al., 1995) . More recently, bcl-2 expression was found to protect prostatic glandular epithelial cells from androgen-ablation in vivo (Bruckheimer et al., 2000) . It was, therefore, of interest to assess whether bcl-2 could accelerate androgen-independent tumor progression in vivo using the BxT mice. TRAMP mice were castrated at 12 weeks of age and the incidence of hormone-independent prostate tumors assessed by light microscopy after 12 weeks. Prostate carcinoma was detected in 36% of the TRAMP mice following castration. This incidence is somewhat less than previously reported (Gingrich et al., 1997) which may in part be attributable to dierences in the genetic background ([C57BL/66FVB]F 1 versus C57BL/6, respectively) of the mice used in these experiments. In contrast, histologic evidence of carcinoma was observed in only 11% of BxT mice following castration. The signi®cance of this, somewhat unanticipated, observation is unknown but several factors may have contributed to this outcome. Immunoblot analysis revealed that the level of LTA protein in prostates of BxT mice was approximately 1.5 ± 3-fold lower than that observed in TRAMP prostates. It might then be expected that the contribution of LTA to the development of androgen-independent prostate cells in BxT mice would be correspondingly reduced. It is relevant in this regard that castration of TRAMP mice at 4 weeks of age (Eng et al., 1999) rather than 12 weeks of age (Gingrich et al., 1997) signi®cantly delayed or completely prevented the development of prostate cancer. These ®ndings are consistent with a dosage/duration eect of transgene expression for the acquisition of androgen-independent growth in prostate cancer cells. Furthermore, early castration was associated with a sustained suppression of LTA expression in the TRAMP mice that did not develop carcinomas. Those animals that developed carcinomas, however, exhibited expression of the LTA transgene (Eng et al., 1999; Gingrich et al., 1997) .
In contrast to LTA in the TRAMP mice, castration resulted in loss of detectable levels of transgenic bcl-2 expression in the BxT mice. This limitation, therefore, precludes the ability to directly assess whether bcl-2 could accelerate the development of androgen-independent tumor growth in this model system. In this regard, however, we have examined prostate carcinomas arising in intact and castrate TRAMP mice for evidence of modulations in bcl-2, bax, and bcl-x proteins using immunoblotting techniques. Our ®nd-ings suggest that alterations in the levels of these proteins does not contribute to androgen-independent prostate cancer growth in this model system. Our ®ndings further suggest that expression of the bcl-2 transgene in BxT mice may interfere with the molecular mechanisms necessary for the generation of androgenindependent tumor cells resulting from expression of LTA. If, in fact, this is the case then it could be anticipated that androgen-independent prostate cancers, characteristically expressing high levels of bcl-2 protein, would be sensitive to therapeutic strategies designed to interupt bcl-2 function or downregulate the protein. It might be anticipated that pre-existing carcinomas would regress following castration in BxT mice. Further, these ®ndings imply the existence of molecular mechanisms enabling androgen-independent tumor growth that do not appear to involve alterations in bcl-2 gene family members.
Materials and methods
Production and screening of transgenic mice
The generation of TRAMP and probasin-bcl-2 transgenic mice, tail DNA isolation, and PCR screening was described previously (Greenberg et al., 1994 (Greenberg et al., , 1995 Bruckheimer et al., 2000) . BxT (Bcl-2xTRAMP) mice, which simultaneously express deregulated bcl-2 and SV40 early genes in the prostate, were generated from crossing the C57BL/6 probasin-bcl-2 mice with the TRAMP mice.
Wet weight determinations and light microscopy
Prostate size was determined by weighing the ventral and dorsolateral prostate separately from control littermate, bcl-2, TRAMP, and BxT prior to ®xation for histologic examination. Hematoxylin and eosin (H&E) stained sections obtained from control littermate, bcl-2, TRAMP, and BxT mice at 8, 12, 16, 18, 20, 24 , and 28 weeks of age were examined without the knowledge of genotype by light microscopy. Sections were given a designation of a histologic grade: normal, low grade prostatic intraepithelial neoplasia (PIN), high grade PIN, and carcinoma in situ (CIS), and invasive carcinoma. The incidence of metastases was assessed by gross examination of the animal at autopsy and by light microscopic examination of organs.
Hormone-independent prostate cancer
At 12 weeks of age, the control littermate, bcl-2, TRAMP, and BxT mice were castrated. Brie¯y, animals were anesthetized with metophane. A lateral incision was made into the scrotum and the testes ligated and removed. The incision was closed with surgical silk. At 24 weeks of age, 12 weeks following castration, the ventral and dorsolateral lobes of the prostate and other tissues were harvested and processed for light microscopic examination.
Immunohistochemical analyses
Ventral and dorsolateral prostate tissue was ®xed overnight in 10% phosphate-buered-formalin and then subjected to standard tissue processing. Tissue sections were placed in OCT, snap frozen, and stored at 7808C until sectioning. All sections were stained with H&E and reviewed by light microscopy. Expression of transgenic human bcl-2 was evaluated on frozen sections. Tissue was ®xed in cold acetone for 10 min, washed, treated with 0.1% H 2 O 2 in methanol for 10 min, washed, and blocked in 10% goat serum in PBS for 30 min. Sections were incubated with primary anti-human bcl-2 antibody (hamster monoclonal Pharmingen 6C8 #15131A, 1 : 50 dilution) for 1 h followed by incubation with secondary antibody (goat anti-hamster HRP antibody Jackson ImmunoResearch #107-035-142, 1 : 200 dilution) for 45 min. Antigen was detected using the Vectastain ABC kit (PK4000, Vector Laboratories, Burlingame, CA, USA) and counterstaining with hematoxylin. SV40 Large T antigen was detected in paran sections using the DAKO antigen retrieval reagent, incubating with primary antibody (mouse monoclonal Pharmingen #14111A, 1 : 100 dilution) for 2 h, and secondary antibody (sheep anti-mouse HRP Amersham #NA 931, 1 : 100 dilution) for 1 h. Antigen was detected using the ABC kit, and counterstaining with hematoxylin.
Western blot analysis
Ventral and dorsolateral prostates were homogenized through an 18 gauge needle (50 strokes) in Triton X 100 (TX100) lysis buer (15 mM NaCl, 25 mM Tris pH 7.4, 1% TX100, 100 mM sodium orthovanadate, 1 mM PMSF, and 2 mg/ml aprotonin). Other tissues were harvested and homogenized in TX100 buer using the Brinkman Polytron Tissue Homogenizer. Protein content was assayed using the Biorad protein assay (Biorad, Hercules, CA, USA). Aliquots of protein (60 mg) were loaded on 7%/14% SDS stacked polyacrylamide gels. After electrophoresis, proteins were electrotransferred to nitrocellulose membrane. Membranes were blocked with 5% dry milk in PBS-T (phosphate buered saline containing 0.05% Tween 20) for 1 h at room temperature then incubated with the primary antibody overnight at 48C. The expression of human bcl-2 (hamster monoclonal Pharmingen 6C8 #15131A, 1 : 1000 dilution), murine bcl-2 (hamster monoclonal Pharmingen 3F11 #15021A, 1 : 1000 dilution), bax (rabbit polyclonal Santa Cruz #sc-493, 1 : 500), bcl-x L (rabbit polyclonal Santa Cruz #sc-634, 1 : 500 dilution), and SV40 T antigen (mouse monoclonal Pharmingen #14111A, 1 : 1000 dilution) proteins were determined. Following incubation with primary antibody, the membranes were washed and incubated with species speci®c horse-radish peroxidase labeled secondary antibodies for 1 h at room temperature (goat anti-hamster HRP antibody Jackson ImmunoResearch #107-035-142, 1 : 1000 dilution, sheep anti-mouse HRP Amersham #NA 931, 1 : 1000 dilution or donkey anti-rabbit HRP Amersham #NA 934, 1 : 1000 dilution). Membranes were subsequently incubated with the enhanced chemiluminescence system (ECL, Amersham Life Sciences) for 1 min and autoradiographed using X-ray ®lm (Amersham).
Apoptosis detection by TUNEL staining
Ventral and dorsolateral prostates were harvested from 12-week-old control littermate, probasin-bcl-2, TRAMP, and BxT transgenic mice. The tissue was ®xed overnight in 10% phosphate-buered-formalin and processed for paran embeddment. TUNEL staining was performed according to established procedures (Gavrieli et al., 1992) . Brie¯y, tissue sections were deparanized in xylene then rehydrated in ethanol. The sections were then incubated with proteinase K (0.02 mg/ml) for 15 min at 318C. Endogenous peroxidases were removed by incubation with 2% H 2 O 2 for 5 min at room temperature. The labeling reaction occurred for 1 h at 378C using UTP (1 : 200 dilution) and TdT (1 : 400 dilution) in the presence of Mn
2+
. Incubation with strepavidin-horseradish peroxidase for 45 min followed by incubation with AEC for 15 min enabled detection of cells that incorporated dUTP. Sections were counterstained with hematoxylin. Positive controls consisted of a tissue section incubated with 10 mg/ml DNase prior to proteinase K treatment. Apoptosis was quantitated by scoring 500 epithelial cells per ®eld in ®ve random ®elds per tissue section.
BrdU incorporation and immunohistochemistry
Control littermate, bcl-2, TRAMP, and BxT mice, at 8 weeks of age, were injected intraperitoneally, with 5.5 mg/100 g body weight BrdU (Sigma #B0631). A second injection was performed 2 h after the ®rst and the ventral and dorsolateral prostates were harvested 2 h after the second injection. Tissues were ®xed overnight in 70% cold EtOH, dehydrated in 100% EtOH, placed in xylene for 24 h followed by paran embedding. Immunohistochemical detection of cells that incorporated BrdU was performed by deparanizing sections, treating with 2N HCl, treating and blocking with 1% goat serum in 30% methanol +0.3% H 2 O 2 . Sections were incubated with primary anti-BrdU antibody (mouse monoclonal Becton Dickinson #347580, 1 : 50 dilution) for 1 h followed by incubation with secondary antibody (sheep antimouse HRP Amersham #NA 931, 1 : 100 dilution) for 1 h. Cells incorporating BrdU were visualized using the Vectastain ABC kit (PK4000, Vector Laboratories, Burlingame, CA, USA) and counterstained with hematoxylin. Proliferation was quantitated by scoring 500 epithelial cells per ®eld in ®ve random ®elds per tissue section.
Statistical analyses
Paired T-tests were used to assess basal apoptosis with a con®dence value of 95%. The Mann-Whitney/Wilcoxon rank sum test was performed on the BrdU incorporation/ proliferation data where LTA was the independent variable. For wet weight determinations, the Mann-Whitney/Wilcoxon rank sum test was also performed with SV40 T antigen as the independent variable. The incidence of carcinoma in situ and prostate cancer was analysed by chi-square analysis where both the Pearson value and the Mantel-Haenszel test for linear association were used to determine signi®cant interactions between SV40 early genes and bcl-2.
